1,560
Participants
Start Date
October 1, 2010
Primary Completion Date
January 1, 2014
Study Completion Date
April 7, 2016
Orteronel
Orteronel will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of \<50 ng/dL.
Placebo
Placebo will be administered orally twice a day continuously throughout the study. Additionally, all patients will receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and a testosterone concentration of \<50 ng/dL.
Prednisone
Prednisone will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of \<50 ng/dL.
Anchorage
Tucson
Duarte
Highland
Orange
Sacramento
San Francisco
Aurora
Denver
Deerfield Beach
Fort Myers
Jacksonville
Orlando
Port Saint Lucie
Jeffersonville
Kansas City
New Orleans
Baltimore
Boston
Lansing
Duluth
Corinth
Columbia
Jefferson City
Omaha
Las Vegas
Hackensack
East Syracuse
New York
Durham
Raleigh
Kettering
Tualatin
Hershey
Lancaster
Philadelphia
Piitsburgh
Charleston
Columbia
Chattanooga
Nashville
Amarillo
Bedford
Dallas
Denton
Tyler
Salt Lake City
Norfolk
Garran
Hobart
Kurralta Park
Nedlands
Perth
Redcliffe
Wodonga
Graz
Linz
Vienna
Minsk
Edegem
Hasselt
Kortrijk
Leuven
Namur
Bairro Nazare - Salvador
Barretos/sp
Belo Horizonte
Campinas
Caxias do Sul
Curitiba
Fortaleza/ce
Ijuí
Joinville
Lajeado - Rs
Piracicaba - Sp
Porto Alegre- Rs
Porto Alegre/rs
Ribeirao Preto - Sp
Rio de Janeiro
Rio de Janeiro Rj
Santo André
São José do Rio Preto
São José dos Campos
São Paulo
Sorocaba - Sp
Plovdiv
Sofia
Varna
Kelowna
Burlington
Hamilton
London
Owen Sound
Toronto
Montreal
Pointe-Claire
Québec
Sherbrooke
Las Condes
Santiago
Temuco
Valparaíso
Santiago de Cali
Hradec Králové
Prague
Joensuu
Oulu
Seinäjoki
Tampere
Angers
Bordeaux
Caen
Créteil
La Roche-sur-Yon
Lyon
Marseille
Nancy
Nantes
Paris
Poitiers
Saint-Etienne
Villejuif
Braunschweig
Dresden
Hamburg
Hanover
Kassel
Kempen
Nürtingen
Tübingen
Wuppertal
Athens
Heraklion Crete
Larissa
Pátrai
Thessaloniki
Kowloon
Shatin
Dublin
Galway
Haifa
Holon
Jerusalem
Petah Tikva
Ramat Gan
Tel Aviv
Ẕerifin
Aviano
Novara
Roma
Torino
Chiba
Fukuoka
Hamamatsu
Hokkaido
Kanazawa
Kita-gun
Maebashi
Mito
Osaka
Sakura
Sayama
Sendai
Shimizucho Sunto-gun
Suntou-gun
Tokyo
Yamagata
Yokohama
Yufu
Riga
Kaunas
Klaipėda
Vilnius
Durango Durango
Mexico City Distrito Federal
Zapopan Jalisco
Amsterdam
Arnhem
Breda
Eindhoven
Heerlen
Nieuwegein
Nijmegen
Rotterdam
Auckland
Christchurch
Dunedin
Takapuna
Tauranga
Lima
Bielsko-Biala
Wroclaw
Liepaja
Lisbon
Porto
San Juan
Bucharest
Cluj-Napoca
Moscow
Saint Petersburg
Singapore
Nitra
Prešov
Trenčín
Žilina
Cape Town
Durban
George
Port Elizabeth
A Coruña
Barcelona
Madrid
Majadahonda
Pamplona
Seville
Valencia
Gothenburg
Stockholm
Uppsala
Aarau
Lausanne
Winterthur
Zurich
Taichung
Taipei
Dnipropetrovsk
Donetsk
Kyiv
Zaporizhzhya
Aberdeen
Belfast
Bristol
Cottingham
Coventry
Glasgow
London
Manchester
Northwood
Preston
Southampton
Lead Sponsor
Millennium Pharmaceuticals, Inc.
INDUSTRY